OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate the Selective SIRPα antagonist BI 765063* under Development in Collaboration with Boehringer Ingelheim in Patients with Advanced Solid Tumors

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing